bioMerieux SA, Gen-Probe deal

In a cross-licensing deal, bioMerieux received a limited, nonexclusive license to use GPRO's ribosomal RNA technologies, and GPRO received a nonexclusive license to bioMerieux's IP for detecting genetic mutations associated with a predisposition for blood clotting disorders.

bioMerieux paid GPRO $250,000 for a research license and the option to use GPRO's technology to develop diagnostics for certain targets. bioMerieux may exercise its options for $4.5 million in January 2005 and may acquire rights to develop products for other targets for $3 million by the end of 2006. GPRO also will be eligible for royalties. GPRO will pay bioMerieux $1 million for the IP license and will owe royalties on products it develops. ...